SGLT2 Inhibitors: The Cardiorenal Drug With Serious Longevity Potential
SGLT2 inhibitors were developed for diabetes. Their cardiorenal protection data is among the most impressive of any drug class in the last decade — and researchers think the longevity implications go further.
SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) were approved for type 2 diabetes management. Their cardiovascular and kidney protection data — accumulated in large outcome trials — has made them one of the most exciting drug classes in medicine.
How they work
SGLT2 (sodium-glucose cotransporter 2) is a protein in the kidney that reabsorbs glucose from urine back into the bloodstream. SGLT2 inhibitors block this reabsorption, causing excess glucose to be excreted in urine. The result: lower blood glucose, modestly lower blood pressure, and mild caloric deficit (from glucose excretion).
But the mechanisms relevant to longevity extend well beyond glucose lowering.
The cardiorenal outcome trials
The EMPA-REG OUTCOME trial (empagliflozin, 2015) was a watershed moment. In diabetic patients with cardiovascular disease, empagliflozin reduced: - Cardiovascular mortality by 38% - Heart failure hospitalization by 35% - Progression of kidney disease by 39%
These were drug trial results unlike almost anything seen since statins. Subsequent trials (DAPA-HF, EMPEROR-Reduced) extended the cardiovascular benefit to heart failure patients without diabetes.
The kidney protection data is similarly impressive — multiple trials showing significant reduction in progression to end-stage renal disease.
The longevity mechanisms
Beyond the trial data, SGLT2 inhibitors appear to:
- Mimic caloric restriction signaling (AMPK activation, mTOR suppression)
- Induce mild ketosis (ketone bodies as a "superfuel" for the heart and brain)
- Reduce visceral fat
- Lower uric acid
- Reduce inflammation markers
These mechanisms overlap with known longevity pathways, leading researchers like Peter Attia and others to view SGLT2 inhibitors as potentially valuable longevity interventions even in non-diabetic patients.
The evidence gap for non-diabetics
The current evidence base is largely in diabetic or cardiovascular-risk populations. Trials in non-diabetic healthy individuals are limited. This is why our SGLT2 stack is currently in development (waitlist) — we're waiting for the evidence base and clinical protocols to mature before offering it routinely.
The trajectory of the evidence strongly suggests benefit. We expect to offer this stack in 2026.